Niedźwiedzi
Pfizer's stock declines 0.42% amid new patent lawsuits over COVID-19 vaccine technology.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock experienced a slight decline of 0.42% following the announcement of new international patent lawsuits filed by Arbutus Biopharma and Genevant Sciences. These lawsuits target Pfizer/BioNTech's use of mRNA lipid nanoparticle technology in their COVID-19 vaccine, seeking injunctions and monetary damages across Canada and much of the European Union. This legal action extends existing U.S. patent disputes into multiple major markets, potentially impacting Pfizer's mRNA franchise.
Kluczowe punkty
- Arbutus Biopharma and Genevant Sciences file new international patent lawsuits against Pfizer/BioNTech over mRNA lipid nanoparticle technology.
- Pfizer's stock price declines 0.42% to $24.82 amid the patent litigation news.
- The lawsuits seek injunctions and monetary damages across Canada and much of the European Union related to Pfizer/BioNTech’s use of LNP technology.
Źródła
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
